Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT04439123 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Start date: May 31, 2016
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of AZD5363 in patients whose cancer has a genetic change called AKT mutation. AZD5363 may block AKT, which is a protein needed for cancer cell growth. Researchers hope to learn if AZD5363 will shrink this type of cancer or stop its growth.

NCT ID: NCT04439110 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

Start date: August 12, 2015
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial identifies the effects of ado-trastuzumab emtansine in patients whose cancer has a genetic change called HER2 amplification. Ado-trastuzumab emtansine is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called DM1. Trastuzumab is a form of "targeted therapy", because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors and delivers DM1 to kill them. Researchers hope to learn if the study drug will shrink this type of cancer or stop its growth.

NCT ID: NCT04439006 Completed - Clinical trials for Myelodysplastic Syndrome

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Start date: October 23, 2020
Phase: Phase 1
Study type: Interventional

This phase Ib/II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization. Ibrutinib may help improve COVID-19 symptoms by lessening the inflammatory response in the lungs, while preserving overall immune function. This may reduce the need to be on a ventilator to help with breathing.

NCT ID: NCT04438382 Terminated - Clinical trials for Malignant Solid Neoplasm

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Start date: January 7, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well infliximab and intravenous immunoglobulin therapy work in treating patients with pneumonitis that does not respond to steroid treatment. Immunotherapy with monoclonal antibodies such as, infliximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Intravenous immunoglobulin therapy may improve pneumonitis. It is not yet known whether giving infliximab and intravenous immunoglobulin therapy will work better in treating patients with pneumonitis.

NCT ID: NCT04437719 Completed - COVID-19 Clinical Trials

Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic

OBVIONCO
Start date: June 29, 2020
Phase: N/A
Study type: Interventional

This registry will allow to evaluate the correlation of the incidence and evolution of associated symptoms of infection of COVID-19 with the biological and clinical parameters in patients followed in Oncology during the COVID-19 pandemic.

NCT ID: NCT04436835 Active, not recruiting - Clinical trials for Malignant Solid Neoplasm

Psychotherapy (Accelerated Resolution Therapy) for Cancer Related Trauma and Distress

Start date: November 27, 2019
Phase: N/A
Study type: Interventional

This trial studies whether a form of psychotherapy called accelerated resolution therapy can help with cancer distress and psychological trauma. Accelerated resolution therapy is an evidence-based therapy for the treatment of depressive symptoms, trauma, and stress-related disorders. This study may provide evidence to support integration of accelerated resolution therapy into psychological treatment of cancer patients, which may decrease cancer related trauma and distress.

NCT ID: NCT04435756 Recruiting - Germ Cell Tumor Clinical Trials

A Study of miRNA 371 in Patients With Germ Cell Tumors

Start date: July 28, 2020
Phase:
Study type: Observational

This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.

NCT ID: NCT04435444 Active, not recruiting - Advanced Cancer Clinical Trials

Meaning-Centered Intervention for Muslim Patients Who Are Being Treated for Advanced Cancer

Start date: June 15, 2020
Phase: N/A
Study type: Interventional

This study will compare the effectiveness of the Masterful supportive care intervention with that of the non-faith-based active control supportive care intervention, which uses the American Cancer Society's patient education materials, for Muslim patients who have advanced cancers. All 3 sessions may occur within one week or over multiple weeks (nonconsecutively), depending on the participants preference. The participant will have up to 12 weeks from recruitment to complete all sessions and follow up surveys.

NCT ID: NCT04434261 Recruiting - Surgery Clinical Trials

Oncological Surgery in Times of COVID-19: Effectiveness of Preoperative Screening for Sars-Cov-2

ASTANA
Start date: May 11, 2020
Phase:
Study type: Observational

To evaluate the incidence of patients with a positive test for SARS-CoV-2, performed in the preoperative screening for patients treated at the institution

NCT ID: NCT04433494 Recruiting - Breast Cancer Clinical Trials

A Study of TY-302 in Patients With Advanced Solid Tumors

Start date: December 7, 2020
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety and tolerability of TY-302 single and the combination with Tamoxifen in dose-escalation and dose-expansion study.The drugs involved in this study are: - TY-302 - Tamoxifen